About BioGene
BioGene is a company based in Peterborough (United Kingdom) founded in 1993. BioGene offers products and services including CENOS and SoftGenetics Solutions. BioGene operates in a competitive market with competitors including ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity, among others.
- Headquarter Peterborough, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biogene Limited
- Date of Incorporation 17 Mar, 1993
- Jurisdiction HARVARD WAY KIMBOLTON, CAMBRIDGESHIRE
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$700 K (USD), Post-IPO
Dec 29, 2009
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioGene
BioGene offers a comprehensive portfolio of products and services, including CENOS and SoftGenetics Solutions.
Portable system for rapid RT-qPCR testing from crude samples worldwide.
Tools for genetic analysis in diagnostic applications.
Funding Insights of BioGene
Investors in BioGene
BioGene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Locked | Locked | Locked |
Investor details for BioGene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioGene
Investment portfolio details for BioGene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioGene
Detailed financials for BioGene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biogene Comparisons
Peer comparison for BioGene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioGene
BioGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
|
| Locked | Locked | Locked |
Molecular diagnostic devices and reagents are developed and marketed.
|
|
| Locked | Locked | Locked |
Provider of a direct-to-consumer, non-clinical genetic tests
|
|
| Locked | Locked | Locked |
Molecular diagnostic kits for infectious diseases are developed and manufactured.
|
Detailed competitors of BioGene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biogene
Complete news archive for BioGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioGene
BioGene was founded in 1993 and raised its 1st funding round 14 years after it was founded.
BioGene is headquartered in Peterborough, United Kingdom.
BioGene is a molecular biology company based in Cambridge UK that manufactures reagents and instruments for assay design and development, DNARNA purification, amplification and analysis. As of September 2016, the company is also in the process of developing specialized instruments for direct PCR amplification from crude samples, and for POC detection of sepsis called QuRapID and QuType, respectively. Both the instruments are based on the companys proprietary UltraRapid PCR system that consists of a single tube DNA extraction and PCR process and associated reagents and instrumentation. QuRapID is designed for rapid identification of bacteria directly from primary samples using a multiplexed RT-PCR approach. QuType is in development as a POC device for simple and rapid diagnosis of sepsis in patients using the UltraRapid PCR platform.
BioGene offers CENOS and SoftGenetics Solutions.
BioGene has 1 investor. Key investors include National Research Council Canada.